Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A bioadhesive nasal gel product of compound rupatadine and its preparation method

A bioadhesion and bioadhesive technology, which is applied to acute rhinitis bioadhesive gel preparations for the treatment of allergies, can solve the problems of easy occurrence of drug resistance, single curative effect, inconvenient administration, etc., and relieve various symptoms , The effect of even distribution in the nasal cavity and less frequency of medication

Active Publication Date: 2019-05-07
重庆市人民医院
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The purpose of the present invention is to solve the problems in the prior art that the drug for the treatment of allergic rhinitis has a single curative effect, large side effects, prone to drug resistance, and inconvenient administration.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A bioadhesive nasal gel product of compound rupatadine and its preparation method
  • A bioadhesive nasal gel product of compound rupatadine and its preparation method
  • A bioadhesive nasal gel product of compound rupatadine and its preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] A preparation method of compound rupatadine bioadhesive nasal gel, including several formulations;

[0045] The formula and parts by weight of the raw materials are as shown in Tables 1-2;

[0046] Table 1

[0047]

[0048] Table 2

[0049]

[0050] The salt root of rupatadine and its salts includes fumaric acid, benzenesulfonic acid, citric acid, hydrochloric acid or sulfuric acid.

Embodiment 2

[0052] A preparation method of compound rupatadine bioadhesive nasal gel, characterized in that the raw materials include several formulations;

[0053] The formula and parts by weight of the raw materials are as shown in Tables 3-4;

[0054] table 3

[0055]

[0056] Table 4

[0057]

[0058] The salt root of rupatadine and its salts includes fumaric acid, benzenesulfonic acid, citric acid, hydrochloric acid or sulfuric acid.

Embodiment 3

[0060] A preparation method of compound rupatadine bioadhesive nasal gel, the preparation method of which includes several kinds of formulations;

[0061] The formula and parts by weight of the raw materials are as shown in Tables 5-6;

[0062] table 5

[0063]

[0064] Table 6

[0065]

[0066] The salt root of rupatadine and its salts includes fumaric acid, benzenesulfonic acid, citric acid, hydrochloric acid or sulfuric acid.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound rupatadine bioadhesion nasal gel product and a preparation method. The compound rupatadine bioadhesion nasal gel product is characterized by being prepared from, 10-100 parts of rupatadine and salts thereof, 5-20 parts of xylometazoline hydrochloride / naphazoline / pseudoephedrine hydrochloride, 1-4 parts of furacilin, 300-5000 parts of polymer gel materials, 2-200 parts of a biological adhesive, 180-200 parts of a buffer salt, 800-1600 parts of a wetting agent and 20000 parts of sterile water for injection. The wetting agent is dissolved into 2 / 3 of the sterile water for injection to obtain a solution A; the polymer gel material is stirred and added into the solution A to obtain a gel system B; the biological adhesive is dispersed into the gel system B to obtain a gel system C; the rupatadine and salts thereof, the xylometazoline hydrochloride / naphazoline / pseudoephedrine hydrochloride, the furacilin and the buffer salt are successively added into 1 / 3 of the sterile water for injection, and sonication is performed to obtain a solution D; the solution D is dispersed into the gel system C, and stirring is performed to obtain the final product.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a bioadhesive gel preparation for treating allergic and acute rhinitis containing rupatadine and its salt, a vasoconstrictor and an anti-infective drug nitrofurazone. Background technique [0002] Allergic rhinitis is a chronic inflammatory reaction disease of the nasal mucosa after exposure to allergens. The main clinical symptoms are nasal itching, sneezing, nasal congestion, hypersecretion of the nose, swelling of the nasal mucosa, and headache. Although this disease is not fatal, symptoms such as non-stop sneezing, nasal congestion, tearing, and nasal discharge will often seriously affect the patient's normal work, study and life during the attack. Therefore, research on the treatment of this disease has important clinical value. [0003] There are a variety of commonly used drugs for clinical treatment of this disease, covering hormones, antihistamines, mast cell ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4545A61K31/4174A61K31/137A61K31/345A61K9/06A61K47/32A61K47/36A61K47/38A61K47/10A61P11/02A61P29/00A61P37/08
CPCA61K9/0043A61K9/06A61K31/137A61K31/345A61K31/4174A61K31/4545A61K47/10A61K47/32A61K47/36A61K47/38A61K2300/00
Inventor 车坷科周维康曾丹王丽娟
Owner 重庆市人民医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products